Humanized antibodies that recognize alpha-synuclein

Patent metadata

Field	Value
Publication number	US-12528858-B2
Application number	US-202217730074-A
Country	US
Kind code	B2
Filing date	Apr 26, 2022
Priority date	Oct 28, 2011
Publication date	Jan 20, 2026
Grant date	Jan 20, 2026

Abstract

The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.

First claim

What is claimed is:

1 . A method of producing an antibody, comprising culturing cells transformed with a nucleic acid or nucleic acids encoding the heavy and light chains of the antibody of a mature heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 10 linked to a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:32 provided the C-terminal lysine may be omitted, and a mature light chain variable region comprising the amino acid sequence of SEQ ID NO:5 linked to a light chain constant region comprising the amino acid sequence of SEQ ID NO: 13, so that the cell secrete the antibody; and purifying the antibody from cell culture media.

2 . The method of claim 1 , wherein the cells are CHO cells.

3 . The method of claim 1 , wherein the cells are transferred with a nucleic acid or nucleic acids comprising the nucleic acid sequence of SEQ ID NO:20 and SEQ ID NO: 17.

4 . The method of claim 1 , wherein the purification comprises performing one or more of protein A capture, hydrophobic interaction chromatography, ion and exchange chromatography.

5 . The method of claim 4 , further comprising combining the purified antibody with a physiologically acceptable carrier to form a pharmaceutical composition.

6 . A method of producing a cell line producing an antibody, comprising introducing a vector or vectors encoding a mature heavy mature heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 10 linked to a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:32 provided the C-terminal lysine may be omitted, and a mature light chain variable region comprising the amino acid sequence of SEQ ID NO:5 linked to a light chain constant region comprising the amino acid sequence of SEQ ID NO: 13 and a selectable marker into cells; propagating the cells under conditions to select for cells having increased copy number of the vector; isolating single cells from the selected cell; and banking cells cloned from a single cell selected based on yield of antibody.

7 . The method of claim 6 , further comprising propagating the cells under selective conditions and screening for cell lines naturally expressing and secreting at least 100 mg/L/10 6 cells/24 h.

Assignees

• Prothena Biosciences Ltd

Inventors

• Saldanha Jose William
• Nijjar Tarlochan S

Classifications

• G01N33/6854

  Immunoglobulins · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• G01N2800/2835

  Movement disorders, e.g. Parkinson, Huntington, Tourette · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• G01N33/6896

  Neurological disorders, e.g. Alzheimer's disease · CPC title